You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for LOU064


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug LOU064?

LOU064 is an investigational drug.

There have been 17 clinical trials for LOU064. The most recent clinical trial was a Phase 2 trial, which was initiated on November 30th 2021.

The most common disease conditions in clinical trials are Urticaria, Chronic Urticaria, and Sclerosis. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are twelve US patents protecting this investigational drug and two hundred and thirty-nine international patents.

Recent Clinical Trials for LOU064
TitleSponsorPhase
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistaminesNovartis PharmaceuticalsPhase 3
A Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo and With Omalizumab as Active Control in CSU Adult Patients.Novartis PharmaceuticalsPhase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 YNovartis PharmaceuticalsPhase 3

See all LOU064 clinical trials

Clinical Trial Summary for LOU064

Top disease conditions for LOU064
trials01234567891011UrticariaChronic UrticariaSclerosis[disabled in preview]
Top clinical trial sponsors for LOU064
trials024681012141618Novartis Pharmaceuticals[disabled in preview]

See all LOU064 clinical trials

US Patents for LOU064

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
LOU064 ⤷  Subscribe Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Subscribe
LOU064 ⤷  Subscribe CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Subscribe
LOU064 ⤷  Subscribe Treatment of cancer using a CLL-1 chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 3 of 3 entries

International Patents for LOU064

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
LOU064 Argentina AR102035 2034-07-21 ⤷  Subscribe
LOU064 Australia AU2015292744 2034-07-21 ⤷  Subscribe
LOU064 Australia AU2020202726 2034-07-21 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 3 of 3 entries

LOU064 (Remibrutinib): A Comprehensive Update on Development and Market Projections

Introduction to LOU064 (Remibrutinib)

LOU064, also known as Remibrutinib, is a small molecule drug developed by Novartis Pharma AG. It belongs to the class of Bruton's tyrosine kinase (BTK) inhibitors, which are increasingly important in the treatment of various autoimmune and oncological conditions.

Mechanism of Action

Remibrutinib acts by inhibiting BTK, a key enzyme in the B-cell receptor signaling pathway. This inhibition is crucial for treating diseases where B-cell activity is aberrant, such as certain types of leukemia, lymphoma, and autoimmune disorders[1][4].

Current Development Status

As of the latest updates, Remibrutinib is in Phase 3 clinical trials for several indications. Here are some key developments:

  • Chronic Spontaneous Urticaria and Chronic Idiopathic Urticaria: Remibrutinib is being evaluated for its efficacy in treating chronic urticaria, with Phase 3 trials showing positive results[1][4].
  • Multiple Sclerosis: The drug is also under investigation for relapsing multiple sclerosis (RMS), relapsing-remitting multiple sclerosis, and secondary progressive multiple sclerosis (SPMS)[4][5].
  • Atopic Diathesis and Hidradenitis Suppurativa: Additional Phase 3 trials are focused on atopic diathesis and hidradenitis suppurativa, indicating the drug's potential in treating a wide range of autoimmune conditions[4][5].

Market Projections

The BTK inhibitors market, including Remibrutinib, is poised for significant growth driven by advancements in oncology and autoimmune disease treatments.

Market Size and Growth

  • The total market size of BTK inhibitors in the 7 major markets (the United States, EU4, the UK, and Japan) is expected to surge significantly by 2034. For instance, IMBRUVICA, a leading BTK inhibitor, generated approximately USD 3.5 billion in revenue globally in 2023[2].
  • Remibrutinib itself is projected to reach an annual revenue of $847 million in the US by 2034, according to GlobalData’s Expiry Model[5].

Key Drivers

  • Increasing Incidence of Diseases: The rising prevalence of cancers such as leukemia, lymphoma, and multiple myeloma, as well as autoimmune diseases, is driving the demand for more effective and targeted therapies like BTK inhibitors[2].
  • Regulatory Approvals: Regulatory bodies worldwide are increasingly approving BTK inhibitors for various indications, opening up new avenues for market growth and expansion[2].
  • Research and Development: Ongoing clinical research and technological advancements are expected to propel the market forward, with the introduction of next-generation BTK inhibitors and their potential applications in combination therapies[2].

Competitive Landscape

The BTK inhibitors market is dynamic, with several pharmaceutical companies, including Novartis, Ono Pharmaceutical, and Beijing Innocare Pharmaceutical, developing novel BTK inhibitors. Strategic collaborations and partnerships are common among these companies to enhance their research capabilities and expand their market presence[2].

Challenges and Opportunities

  • Pricing Strategies and Reimbursement Policies: Pharmaceutical companies face challenges related to pricing pressures and market access hurdles, which impact their commercialization strategies for BTK inhibitors[2].
  • Clinical Trials and Approval: The success of Remibrutinib in Phase 3 trials and its subsequent regulatory approvals will be crucial for its market entry and acceptance. GlobalData’s report indicates a 67% phase transition success rate (PTSR) for Phase III drugs in the treatment of chronic urticaria, which is a positive indicator for Remibrutinib’s likelihood of approval[4].

Financial Valuation

The financial valuation of Remibrutinib is closely tied to its phase transition success rate and likelihood of approval. GlobalData’s risk-adjusted Net Present Value (NPV) model provides a conservative valuation measure that accounts for the risks associated with drug development. This model is essential for investors and stakeholders to assess the investment opportunity in Remibrutinib[5].

Key Takeaways

  • Phase 3 Trials: Remibrutinib is currently in Phase 3 clinical trials for multiple indications, including chronic urticaria and multiple sclerosis.
  • Market Growth: The BTK inhibitors market is expected to grow significantly by 2034, driven by increasing disease incidence and regulatory approvals.
  • Revenue Projections: Remibrutinib is projected to generate $847 million in annual revenue in the US by 2034.
  • Competitive Landscape: The market is competitive, with several companies developing novel BTK inhibitors and engaging in strategic collaborations.
  • Challenges and Opportunities: Pricing strategies, reimbursement policies, and clinical trial outcomes are critical factors influencing the drug’s market success.

FAQs

What is the mechanism of action of Remibrutinib?

Remibrutinib acts by inhibiting Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway.

Which conditions is Remibrutinib being developed to treat?

Remibrutinib is being developed for the treatment of chronic spontaneous urticaria, chronic idiopathic urticaria, atopic diathesis, hidradenitis suppurativa, and various forms of multiple sclerosis, among other conditions.

What is the current phase of clinical trials for Remibrutinib?

Remibrutinib is currently in Phase 3 clinical trials.

What are the projected revenues for Remibrutinib by 2034?

Remibrutinib is expected to generate $847 million in annual revenue in the US by 2034.

Who are the key players in the BTK inhibitors market?

Key players include Novartis, Ono Pharmaceutical, Beijing Innocare Pharmaceutical, and others.

Sources

  1. Patsnap Synapse: Remibrutinib - Drug Targets, Indications, Patents.
  2. PR Newswire: BTK Inhibitors Market to Observe Stunning Growth by 2034.
  3. GlobalData: Net Present Value Model: Remibrutinib.
  4. Pharmaceutical Technology: Remibrutinib by Novartis for Chronic Urticaria Or Hives.
  5. Pharmaceutical Technology: What is the current valuation of Novartis's Remibrutinib.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.